Gynecologic Cancers Bradley J. Monk, M.D. Associate Professor Division of Gynecologic Oncology Chao Family Comprehensive Cancer Center University of California Irvine Medical…

1. ASCO 2015 LYMPHOMA UPDATE Dr Chandan 2. Lenalidomide in combination with rituximab for relapsed or refractory mantel cell lymphoma: Updated analysis of a phase 2 trial.…

Slide 1 Individualizing Therapy for Gastrointestinal Malignancies 2010 Update Thomas J. Semrad MD, MAS Assistant Professor of Medicine UC Davis Cancer Center Slide 2 Disclosure…

Slide 1 Molecularly-Targeted Cancer Therapy is Here Why is Change So Hard? Slide 2 Advances in DNA Sequencing Technologies We can sequence DNA 1,000 times faster than just…

Randomized, Open Label, Phase III Trial of Figitumumab in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in Patients with Non-Small Cell Lung…

* ASCO Annual Meeting 2013 Poster presentation January 2013 * 5 years results: 734 patients, 7 centres in Germany Absolute number of events in TARGIT vs. EBRT : Primary outcome:…

Bendamustine-Rituximab (B-R) vs CHOP-R Bendamustine-Rituximab (N=139) - Bendamustine 90 mg/m2 day 1+2 Rituximab 375 mg/m2 day 1 CHOP-Rituximab (N=140) - Cyclophosphamide…

Bendamustine-Rituximab (B-R) vs CHOP-R Bendamustine-Rituximab (N=139) - Bendamustine 90 mg/m2 day 1+2 Rituximab 375 mg/m2 day 1 CHOP-Rituximab (N=140) - Cyclophosphamide…

JB 11-11 2009 Sunitinib in Combination with Docetaxel vs. Docetaxel Alone for the First-line Treatment of Advanced Breast Cancer J Bergh,1 R Greil,2 NL Voytko,3 AN Makhson,4…

Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial Eric Van…